Abstract 3541
Background
Cancer follow-up care continues to evolve to incorporate complex programs of supportive care to address long-term disease consequences. However, care may be prescriptive and fragmented, contributing to uncertainty among cancer survivors. As major stakeholders in follow-up care for cancer survivors, nurses are ideally positioned to ensure supportive care is person-centred and responsive to patients’ needs. We recently conducted a study to summarize the evidence related to cancer survivors’ preferences for supportive care and examine the ways in which these preferences are embedded in current guidelines and policies informing cancer survivorship care. This presentation discusses specific implications of these findings for oncology nursing.
Methods
Phase 1 of the study comprises an integrative review of the empirical literature regarding cancer survivors’ preferences for supportive care, with literature sourced from bibilographic databases and analysed according to principles of thematic analysis. In Phase 2, clinical practice guidelines and policy documents guiding supportive care in cancer survivorship are evaluated using content analysis methods to ascertain alignment with the findings of Phase 1. Finally, we conduct a critical analysis of the results through the lens of oncology nursing practice.
Results
Findings of the integrative review and content analysis of practice and policy guidelines highlight issues related to where and when supportive care is accessed and the types and features of supportive care services. Given that these gaps intersect with nursing practice, they serve as potential targets of knowledge translation activities. Impacts on survivors’ experiences are illustrated with exemplars derived from recent qualitative studies conducted in Canadian and Irish contexts.
Conclusions
As novel programs are developed to meet the needs of the growing population of cancer survivors, a consideration of survivors’ preferences is essential. We offer specific ways in which nursing practice and scholarship can be leveraged to ensure the translation of this knowledge into care, making visible the survivors’ voice in this process.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3630 - Results of phase 1 clinical trial of high doses of Seleno-L-methionine (SLM) in sequential combination with Axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients
Presenter: Yousef Zakharia
Session: Poster Display session 3
Resources:
Abstract
2356 - Safety and Efficacy of CDX-014 , an Antibody-Drug Conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced Renal Cell Carcinoma
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
1028 - SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz).
Presenter: Begona P. Valderrama
Session: Poster Display session 3
Resources:
Abstract
2293 - Effect of Antacid Intake on the Therapeutic Efficacy of Sunitinib (SUN) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts): a Sub-Analysis of the STAR-TOR Registry
Presenter: Katrin Schlack
Session: Poster Display session 3
Resources:
Abstract
1451 - Randomized phase 3 trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN Renal 101 Japanese subgroup analysis
Presenter: Motohide Uemura
Session: Poster Display session 3
Resources:
Abstract
4399 - Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)
Presenter: Jindrich Finek
Session: Poster Display session 3
Resources:
Abstract
1344 - Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials
Presenter: Kyaw Thein
Session: Poster Display session 3
Resources:
Abstract
3462 - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
5268 - Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)
Presenter: Sophie Hans
Session: Poster Display session 3
Resources:
Abstract
4235 - First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES Study
Presenter: Cristina Masini
Session: Poster Display session 3
Resources:
Abstract